结肠和直肠癌后的收入和工作损失：一项瑞典全国范围的队列研究

结直肠癌是常见的，预后正在改善。因此，幸存者的幸存者条件（包括财务后果）很重要。这项研究的目的是量化与匹配的比较者相对于匹配比较器的结肠和直肠癌的工人衰减患者的收入和工作损失。该研究利用了来自CRCBase数据库的数据，这些数据是由全国瑞典大肠癌登记册产生的，并包括来自几个Swedish全国登记册的数据。研究期为1995 - 2020年，针对直肠癌患者，结肠癌患者为2007 - 2020年。在I-III期结肠癌治疗的幸存者中，一项基于人群的回顾性全国人群研究研究了。中位回归用于分析收入和可支配收入，以及分析工作损失可能性的逻辑回归。分析了2017年之前诊断出的8863个结直肠癌幸存者的同类，并分析了匹配的52,514个比较器，法律性别和居住县的比较者。诊断后的日历年和日历年之间的收入明显降低，结肠癌患者的收入从31,319欧元到23,924欧元，直肠癌患者的收入从32,636欧元到22,647欧元，而在5年的随访中，收入从未完全康复。可支配收入实际上是没有改变的。在诊断的日历年中，工作损失的可能性从上一年的29.8％增加到25.3％，分别为结肠和直肠癌患者的83.3％和84.4％，从未完全康复。结肠和直肠癌幸存者之间工作损失的可能性相似，但在接受新辅助治疗的直肠癌患者中却更高基金会和斯德哥尔摩癌症协会，并得到斯德哥尔摩县议会与卡罗林斯卡研究所之间的医学培训和临床研究协议（ALF）提供的赠款。

Colorectal cancer is common and prognosis is improving. The conditions of survivors of treatment, including financial consequences, are thus important. The aim of this study was to quantify loss of earnings and work loss in working-age patients with colon and rectal cancer relative to matched comparators.The study utilised data from the CRCBaSe database that is generated from the nationwide Swedish ColoRectal Cancer Register and includes data from several Swedish nationwide registers. The study period was 1995-2020 for rectal cancer patients and 2007-2020 for colon cancer patients. A retrospective population-based nationwide cohort study on earnings, disposable income, and work loss, in survivors of stage I-III colorectal cancer treatment was undertaken. Median regression was used to analyse earnings and disposable income, and logistic regression to analyse the probability of work loss.A cohort of 8863 colorectal cancer survivors diagnosed before 2017 and 52,514 comparators matched on birth year, legal sex, and county of residence, was analysed. There was a clear reduction in earnings between the calendar year prior to and the calendar year after diagnosis, from € 31,319 to € 23,924 for colon cancer patients and from € 32,636 to € 22,647 for rectal cancer patients, and earnings never fully recovered during the 5-year follow-up. Disposable income was practically unaltered. The probability of work loss increased in the calendar year of diagnosis, from 29.8% to 25.3% the previous year to 83.3% and 84.4% for colon and rectal cancer patients respectively, and never fully recovered. The probability of work loss was similar between colon and rectal cancer survivors, but was higher among patients with rectal cancer who had received neoadjuvant therapy.This study shows that despite an extensive welfare system providing maintained disposable income, there is a financial burden in the form of increased risk of work loss and a reduction in earnings among survivors of colorectal cancer.The study was supported by the Swedish Cancer Society, the Swedish Cancer and Allergy Foundation, and the Stockholm Cancer Society, and supported by grants provided by the Regional Agreement on Medical Training and Clinical Research (ALF) between the Stockholm County Council and Karolinska Institutet.